EMA – New page on Personalised medicine in oncology
EMA recently published on its website a new page dedicated to Personalised medicine in oncology giving more information on its role in this area.
The European Medicines Agency (EMA) offers developers of personalised medicines in oncology several opportunities for early dialogue and consultation before submitting a marketing authorisation.
EMA’s Committee for Medicinal products for Human Use (CHMP) carries out a scientific assessment of the applications and gives a recommendation on whether a medicine should be marketed or not.
The CHMP gives a scientific opinion on the suitability of a companion diagnostic for a specific medicine. This is in line with the In Vitro Diagnostics Regulation.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (11 décembre 2025). EMA – New page on Personalised medicine in oncology. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/15buy





